Sghirlanzoni A, Pareyson D, Benvenuti C, Cei G, Cosi V, Lombardi M, Nicora M, Ricciardi R, Cornelio F
Istituto Neurologico C. Besta, Milan, Italy.
J Neurol. 1992 Mar;239(3):165-9. doi: 10.1007/BF00833919.
The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.
对22例全身型重症肌无力(MG)患者测试了经鼻给予新斯的明的疗效。事实证明,对血管高度丰富的口咽进行局部治疗在临床和电生理方面均在5 - 15分钟内迅速起效。随后从不同中心招募了28例MG患者,并在2至3周的时间内将他们早晨口服吡啶斯的明的剂量替换为经鼻给予新斯的明。经鼻给予新斯的明在该治疗方案中同样有效。即使以这种方式治疗1年的4例患者也未观察到副作用。经鼻给予抗乙酰胆碱酯酶可能非常有益:(1)对于口服剂量吸收不规则的患者;(2)在清晨以及每次需要快速和临时效果时;(3)在延髓功能障碍和紧急情况下,此时便捷的雾化器可能会挽救生命。